



RSV Prevention Clinic

CLINIC HOMECARE (SYNAGIS ONLY)

PH: 937-641-5346 Fax: 937-641-3229

One Children's Plaza • Dayton, OH 45404-1815 • childrensdayton.org

PLEASE PRINT (ALL INFORMATION IS REQUIRED)

Date of Request: _____

PATIENT INFORMATION

Patient's Name: _____

M F DOB: _____ MR# _____

Parent/Guardian Name(s): _____

Home Phone: _____

Work Phone: _____

Cell Phone: _____

Preferred Contact Phone: Work Cell Home

Email Address: _____

Patient is in custody of: Parents Guardian CSB

Address: _____ County: _____

City: _____ State: _____ Zip: _____

1st Insurance: _____ Phone: _____

Cardholder: _____ ID#: _____

2nd Insurance: _____ Phone: _____

Cardholder: _____ ID#: _____

Insurance preauthorization is based on eligible criteria

We will initiate preauthorization and contact patient to schedule appointment

REFERRING PROVIDER INFORMATION

Primary Care Provider: _____

Referring: _____

Phone: _____ Fax: _____

Provider Signature: _____

Date: _____ (required)

Prescription Orders

This Practitioner signed referral is for administration of Beyfortus or Synagis per Dayton Children's protocol during the identified RSV Season. Current dosing information listed below.

Beyfortus™ (nirsevimab-alip) or Synagis® (Palivizumab) administration is appropriate for patient. Final treatment decision will be made based on the current Dayton Children's protocols and insurance site of care and medication preference during authorization process

Synagis® (Palivizumab) administration preferred for patient

Reason Synagis Preferred: _____

Beyfortus™ (nirsevimab-alip) administration preferred for patient

Beyfortus not available to patient outside of RSV prevention clinic

Other : _____

The RSV Prevention Clinic will begin on or after September 1. The RSV season will be identified by the Division of Infectious Disease at Dayton Children's.

- If a patient receives Synagis then he or she will receive: one dose per month of IM palivizumab at a dosing strength of 15 mg/kg, with a maximum total of 5 once-monthly doses to be given during the course of the RSV season.
- If a patient receives nirsevimab, then: infants entering their first RSV season who weigh < 5 kg at the time of injection will receive a single 50 mg IM dose of nirsevimab, while infants entering their first RSV season who weigh > 5 kg at the time of injection will receive a single 100 mg IM dose of nirsevimab. For high-risk infants entering their second RSV season who receive nirsevimab, a single 200 mg IM dose of nirsevimab administered as two concurrent 100 mg IM injections will be provided.

Gestational age at birth _____ weeks _____ days Birth weight: _____ Current weight: _____ kg lbs

Allergies: _____ Date of last weight: _____

Did the patient spend time in NICU? No Yes, provide NICU discharge summary

Date of inpatient dose administered if any: _____ Hospital: _____

To be considered for Treatment at the RSV Prevention Clinic patients must meet at least one of the following recommended criteria:

ICD-10 Code: _____

1. Premature infants, ≤ 12 months of age on August 1, without chronic lung disease of prematurity or congenital heart disease with gestational age of less than 29 week, 0 days

2. Premature infants with chronic lung disease

Infant ≤ 12 months of age on August 1 born before 32 weeks, 0 days gestational age and has a requirement for > 21% oxygen for at least the first 28 days after birth

Year two of life: infants who met the first year definition of chronic lung disease and continue to require medical support:

In the six months prior to August 1, has the patient received any of the following medical treatment (check all that apply)

Supplemental oxygen

Diuretic

Corticosteroid therapy

List medications: _____

3. Infants who are ≤ 12 months of age with hemodynamically significant congenital heart disease.

Please include visit summary information from cardiac consult

Infants with acyanotic heart disease who are receiving medication to control congestive heart failure and will require cardiac surgical procedures

Infants with moderate to severe pulmonary hypertension

Infants with cyanotic heart defects

4. Children < 2 years of age who undergo cardiac transplantation during the RSV season

5. Infants who are ≤ 12 months of age with neuromuscular disease or congenital anomaly that impairs the ability to clear secretions from the upper airway because of ineffective cough

6. Children < 24 months of age who are profoundly immunocompromised during RSV season

7. Children with cystic fibrosis

Infants who are ≤ 12 months of age with cystic fibrosis and clinical evidence of chronic lung disease and/or nutritional compromise

Infants who are in the second year of life and have manifestations of severe lung disease (previous hospitalization for pulmonary exacerbation in the first year of life or abnormalities on chest x-ray or chest CT that persist when stable) or weight for length less than 10th percentile.

Please include any additional relevant clinical documentation to assist with Insurance authorization